Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ATL-105
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Recipient : Northway Biotechpharma
Deal Size : Undisclosed
Deal Type : Partnership
AATec, Northway Biotech Partner to Develop ATL-105 Production for Lung Disease
Details : The Partnership is established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin. It is being evaluated for Non-cystic fibrosis bronchiectasis.
Product Name : ATL-105
Product Type : Protein
Upfront Cash : Undisclosed
July 15, 2025
Lead Product(s) : ATL-105
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Recipient : Northway Biotechpharma
Deal Size : Undisclosed
Deal Type : Partnership
Reset All
